Cefixime + AzithromycinThird Party Manufacturing in India

Cefixime and Azithromycin work through two complementary mechanisms to eliminate bacterial infections. Cefixime, a third-generation cephalosporin, exerts its bactericidal effect by binding to penicillin-binding proteins located within the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, disrupting the structural integrity of the cell wall and causing bacterial cell lysis and death. Cefixime is highly stable against beta-lactamase enzymes, making it effective against many organisms resistant to penicillins and earlier cephalosporins.

Azithromycin, a macrolide antibiotic belonging to the azalide subclass, works by binding reversibly to the 50S ribosomal subunit of susceptible bacteria. This binding blocks the translocation step of protein synthesis, inhibiting bacterial protein production and preventing growth and replication. Unlike Cefixime which kills bacteria directly, Azithromycin is primarily bacteriostatic, though at higher concentrations it can be bactericidal against certain organisms.

Together, this combination provides broad-spectrum coverage against both Gram-positive and Gram-negative bacteria. Cefixime targets the cell wall synthesis pathway while Azithromycin blocks protein synthesis, creating a dual attack that can overcome bacterial resistance mechanisms and provide effective treatment for polymicrobial infections.

Therapeutic Uses

Cefixime + Azithromycin combination is prescribed for the treatment of:

• Respiratory Tract Infections: Effective against community-acquired pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis caused by susceptible organisms including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
• Upper Respiratory Infections: Used for pharyngitis, tonsillitis, sinusitis, and acute otitis media, particularly when bacterial resistance to single-agent therapy is suspected.
• Skin and Soft Tissue Infections: Active against uncomplicated skin infections caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes.
• Urinary Tract Infections: Effective against uncomplicated UTIs caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
• Typhoid Fever: Used in enteric fever where multi-drug resistant Salmonella typhi is prevalent.

Why Manufacturers Choose Cefixime + Azithromycin

The Cefixime + Azithromycin fixed-dose combination is one of the most popular antibiotic combinations in the Indian pharmaceutical market. Its dual mechanism provides broad coverage and reduces resistance development risk, making it preferred for respiratory and ENT infections. The tablet formulation at 200mg + 250mg strength is convenient for once or twice-daily dosing, improving patient compliance. Indian manufacturers produce this combination in large volumes for both domestic PCD franchise networks and export markets across Africa, Asia, and Latin America. With WHO-GMP certified facilities, Indian manufacturers supply this high-demand combination at competitive prices.